---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044599"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:43:05.085250+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q3 revenue record $1.81M (+16.3% YoY); net loss $7.89M; submits PMA to FDA for CGuard Prime

## Summary
- Revenue record $1.81M, up 16.3% YoY; gross margin 22.9% down from 28.1% due to higher costs.
- Net loss $7.89M ($0.16/share) vs $5.18M ($0.15/share) in Q3 2023; operating expenses rose 46% to $8.88M.
- Submitted PMA to FDA for CGuard Prime carotid stent; targets U.S. approval in H1 2025.
- IDE approved for CGUARDIANS II pivotal study of CGuard Prime for TCAR procedures.
- Cash and marketable securities $40.4M at Sept 30, 2024; new Miami HQ to support U.S. launch.

## SEC filing metadata
- accession: 0001493152-24-044599
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315224044599/0001493152-24-044599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315224044599/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044599
- JSON: https://secwatch.observer/filing/0001493152-24-044599.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.